Cortexyme touted new preclinical data for its atuzaginstat (COR388) drug candidate in treating periodontal disease at the 2021 International Association for Dental Research (IADR) virtual meeting.
The drug candidate was able to engage with and inhibit its target, lysine-gingipain from Porphyromonas gingivalis, within a biofilm and disrupt the biofilm integrity, the company said. In addition, a second-generation lysine-gingipain inhibitor, COR588, demonstrated biofilm penetration and target engagement similar to atuzaginstat, according to Cortexyme.
The company plans to begin phase I studies in the third quarter of 2021.
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
